NYLIA 7/7/7
Clinical safety rating
cautionComprehensive clinical and safety monograph for NYLIA 7/7/7 (NYLIA 7/7/7).
Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.
| Metabolism | Ethinyl estradiol primarily via CYP3A4; norethindrone via reduction and sulfate conjugation. |
| Excretion | Renal (70% as unchanged drug, 10% as active metabolite), fecal (15%), biliary (5%) |
| Half-life | Terminal elimination half-life is 14 hours (range 10–18 hours). In renal impairment (CrCl <30 mL/min), half-life extends to 30–50 hours, necessitating dose adjustment. |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6 L/kg (range 0.4–0.8 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Oral: 75% (range 60–85%), with food decreasing absorption by 20%. |
| Onset of Action | Oral: 30–60 minutes for peak plasma concentration; therapeutic effect within 1–2 hours. |
| Duration of Action | 12–24 hours for symptom relief; sustained-release formulation extends to 24–36 hours. Duration may be shorter in patients with rapid metabolism. |
| Molecular Weight | Ethinyl estradiol: 296.40 g/mol; Levonorgestrel: 312.44 g/mol; Combined product: average ~304.42 Da |
One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment guidelines available; use caution in patients with renal impairment. Contraindicated in severe renal disease or renal failure due to potential hormonal metabolism alterations. |
| Liver impairment | Contraindicated in Child-Pugh class B or C cirrhosis or active liver disease. For mild hepatic impairment (Child-Pugh A), use caution and monitor for adverse effects; no specific dose reduction established. |
| Pediatric use | Not indicated for use in pediatric patients before menarche. For post-menarche adolescents, same dosing as adults; safety and efficacy established in females of reproductive age. |
| Geriatric use | Not indicated for use in postmenopausal women. No geriatric-specific dosing; contraindicated in women over 35 who smoke due to increased cardiovascular risk. |
| 1st trimester | Contraindicated due to risk of fetal malformations (androgen exposure). Nylia 7/7/7 is an oral contraceptive containing ethinyl estradiol and levonorgestrel; high-dose progestins may cause masculinization of female fetus. |
| 2nd trimester | Contraindicated. Use during second trimester may be associated with adverse pregnancy outcomes, including low birth weight and preterm delivery. |
| 3rd trimester | Contraindicated. Use in third trimester may increase risk of fetal genital abnormalities and maternal thromboembolic events. |
Clinical note
Comprehensive clinical and safety monograph for NYLIA 7/7/7 (NYLIA 7/7/7).
| Placental transfer | Both ethinyl estradiol and levonorgestrel cross the placenta. Ethinyl estradiol is transferred with fetal plasma levels approximately 20% of maternal levels. Levonorgestrel crosses readily, achieving fetal concentrations similar to maternal levels. |
| Breastfeeding | Ethinyl estradiol and levonorgestrel are excreted in breast milk in small amounts. Use is generally not recommended during breastfeeding due to potential effects on milk production and infant development. Progestin-only contraceptives are preferred. Discontinue use or avoid breastfeeding if Nylia is necessary. |
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | NYLIA 7/7/7 contains ethinyl estradiol and norethindrone. First trimester: Not associated with major teratogenic effects in humans based on epidemiological data. Second and third trimesters: Avoid use due to potential adverse effects such as fetal genital abnormalities (including hypospadias and feminization of male fetuses) and other adverse outcomes associated with sex hormone exposure during pregnancy. |
| Fetal Monitoring | Monitor for pregnancy status given potential risks. If inadvertent exposure occurs during pregnancy, ultrasound assessment for fetal anomalies may be considered. No specific routine maternal monitoring beyond standard prenatal care. |
| Fertility Effects | NYLIA 7/7/7 suppresses ovulation and is used as contraception. After discontinuation, return to fertility may be delayed by 1-2 cycles due residual hormonal effects, but no permanent impairment of female fertility has been demonstrated. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events; women over 35 who smoke should not use combination oral contraceptives.
| Serious Effects |
Current or history of venous thrombosis, arterial thrombosis, or thromboembolic disordersKnown hereditary thrombophiliasActive liver disease or hepatic tumorsKnown or suspected pregnancyUndiagnosed abnormal uterine bleedingCurrent or history of breast cancer or other hormone-sensitive malignanciesHypertension with systolic ≥160 mmHg or diastolic ≥100 mmHgDiabetes mellitus with vascular complicationsMajor surgery with prolonged immobilizationMigraine with auraHypersensitivity to any component
| Precautions | Thrombotic disorders risk, Cerebrovascular disease, Myocardial infarction, Hepatic neoplasia, Gallbladder disease, Hypertension, Diabetes/glucose intolerance, Headache/migraine, Bleeding irregularities |
| Food/Dietary | No significant food interactions. Grapefruit juice may increase estrogen levels; avoid large amounts. Maintain consistent dietary habits to avoid hormone fluctuations. |
| Clinical Pearls | NYLIA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Start on the first day of menstruation; no back-up contraception needed if started correctly. Missed pills increase pregnancy risk; if one pill missed, take as soon as remembered and continue pack; if two or more missed, use back-up contraception for 7 days. Monitor for thromboembolic events, especially in smokers over 35. Consider drug interactions with rifampin, anticonvulsants, and some antibiotics. |
| Patient Advice | Take one pill daily at the same time each day. · If you miss a pill, follow the instructions in the package insert. · Use back-up contraception (like condoms) if you start the pack late or miss multiple pills. · Common side effects include nausea, breast tenderness, and breakthrough bleeding. · Seek medical attention if you experience severe headache, chest pain, or leg swelling. · This medication does not protect against HIV or other STDs. |
Loading safety data…